The Bioenergetic Status Relates to Dopamine Neuron Loss in Familial PD with PINK1 Mutations

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Hilker, Rüediger ^a   Pilatus, Ulrich ^a   Eggers, Carsten ^b   Hagenah, Johann ^c   Roggendorf, Julia ^a   Baudrexel, Simon ^a   Klein, Johannes C ^a   Neumaier, Bernd ^d   Fink, Gereon R ^b   Steinmetz, Helmuth ^a   Klein, Christine ^c   Hattingen, Elke ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BIOENERGY; BRAIN MAPPING; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FAMILIAL DISEASE; FAMILY; FEMALE; GENE; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MALE; MISSENSE MUTATION; PARKINSON DISEASE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PINK1 GENE; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; PUTAMEN;

DOPAMINE; ENERGY METABOLISM; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MUTATION; NEURONS; PARKINSON DISEASE; PROTEIN KINASES;

EID: 84870954776     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051308     Document Type: Article

References (36)

1. Klein C, Djarmati A, Hedrich K, Schafer N, Scaglione C, et al. (2005) PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. Eur J Hum Genet.
2. Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, et al. (2004) PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 56: 336-341.
3. Rakovic A, Grunewald A, Seibler P, Ramirez A, Kock N, et al. (2010) Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Hum Mol Genet 19: 3124-3137.
4. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304: 1158-1160.
5. Thomas KJ, Cookson MR, (2009) The role of PTEN-induced kinase 1 in mitochondrial dysfunction and dynamics. Int J Biochem Cell Biol 41: 2025-2035.
6. Abramov AY, Gegg M, Grunewald A, Wood NW, Klein C, et al. (2011) Bioenergetic Consequences of PINK1 Mutations in Parkinson Disease. PLoS One 6: e25622.
7. Grunewald A, Gegg ME, Taanman JW, King RH, Kock N, et al. (2009) Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. Exp Neurol 219: 266-273.
8. Hoepken HH, Gispert S, Morales B, Wingerter O, Del Turco D, et al. (2007) Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol Dis 25: 401-411.
9. Piccoli C, Sardanelli A, Scrima R, Ripoli M, Quarato G, et al. (2008) Mitochondrial respiratory dysfunction in familiar parkinsonism associated with PINK1 mutation. Neurochem Res 33: 2565-2574.
10. Eggers C, Schmidt A, Hagenah J, Bruggemann N, Klein JC, et al. (2010) Progression of subtle motor signs in PINK1 mutation carriers with mild dopaminergic deficit. Neurology 74: 1798-1805.
11. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18: 738-750.
12. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, et al. (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19: 1020-1028.
13. Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, et al. (2009) Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 132: 3285-3297.
14. Hetherington HP, Pan JW, Mason GF, Adams D, Vaughn MJ, et al. (1996) Quantitative 1H spectroscopic imaging of human brain at 4.1 T using image segmentation. Magn Reson Med 36: 21-29.
15. Gasparovic C, Song T, Devier D, Bockholt HJ, Caprihan A, et al. (2006) Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn Reson Med 55: 1219-1226.
16. Traber F, Block W, Lamerichs R, Gieseke J, Schild HH, (2004) 1H metabolite relaxation times at 3.0 tesla: Measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation. J Magn Reson Imaging 19: 537-545.
17. Zhou C, Huang Y, Shao Y, May J, Prou D, et al. (2008) The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc Natl Acad Sci U S A 105: 12022-12027.
18. Gandhi S, Wood-Kaczmar A, Yao Z, Plun-Favreau H, Deas E, et al. (2009) PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell 33: 627-638.
19. Heeman B, Van den Haute C, Aelvoet SA, Valsecchi F, Rodenburg RJ, et al. (2011) Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. J Cell Sci 124: 1115-1125.
20. Gegg ME, Cooper JM, Schapira AH, Taanman JW, (2009) Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS One 4: e4756.
21. Papa S, Sardanelli AM, Capitanio N, Piccoli C, (2009) Mitochondrial respiratory dysfunction and mutations in mitochondrial DNA in PINK1 familial parkinsonism. J Bioenerg Biomembr 41: 509-516.
22. Almeida A, Almeida J, Bolanos JP, Moncada S, (2001) Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection. Proc Natl Acad Sci U S A 98: 15294-15299.
23. Cholet N, Pellerin L, Welker E, Lacombe P, Seylaz J, et al. (2001) Local injection of antisense oligonucleotides targeted to the glial glutamate transporter GLAST decreases the metabolic response to somatosensory activation. J Cereb Blood Flow Metab 21: 404-412.
24. Prebil M, Jensen J, Zorec R, Kreft M, (2011) Astrocytes and energy metabolism. Arch Physiol Biochem 117: 64-69.
25. Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, et al. (1998) In vivo MR spectroscopy of human dementia. Neuroimaging Clin N Am 8: 809-822.
26. Ross BD, (1991) Biochemical considerations in 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed 4: 59-63.
27. Siger M, Schuff N, Zhu X, Miller BL, Weiner MW, (2009) Regional myo-inositol concentration in mild cognitive impairment Using 1H magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord 23: 57-62.
28. Zhu X, Schuff N, Kornak J, Soher B, Yaffe K, et al. (2006) Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord 20: 77-85.
29. Prestel J, Gempel K, Hauser TK, Schweitzer K, Prokisch H, et al. (2008) Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation. J Neurol 255: 643-648.
30. Thurston JH, Sherman WR, Hauhart RE, Kloepper RF, (1989) myo-inositol: a newly identified nonnitrogenous osmoregulatory molecule in mammalian brain. Pediatr Res 26: 482-485.
31. Brand A, Leibfritz D, Richter-Landsberg C, (1999) Oxidative stress-induced metabolic alterations in rat brain astrocytes studied by multinuclear NMR spectroscopy. J Neurosci Res 58: 576-585.
32. Haussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S, (2000) Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 32: 1035-1038.
33. Valenzuela MJ, Sachdev P, (2001) Magnetic resonance spectroscopy in AD. Neurology 56: 592-598.
34. Pettegrew JW, Klunk WE, Kanal E, Panchalingam K, McClure RJ, (1995) Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Neurobiol Aging 16: 973-975.
35. Pettegrew JW, Panchalingam K, Moossy J, Martinez J, Rao G, et al. (1988) Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease. Arch Neurol 45: 1093-1096.
36. Lin MT, Beal MF, (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787-795.